9 results about "Drug toxicity" patented technology

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

The application relates to the technical field of medicines, and discloses a composition of raltitrexed and a preparation method thereof. The composition of raltitrexed is a full-biodegradable amphiphilic polymer with hydrophilic chitosan and hydrophobic polylactic acid grafted as a carrier, and the composition is combined with carbon nanotubes and chitosan through pi-pi interaction and electrostatic adsorption. The carbon nanotubes have a large specific surface area and strong adsorption capacity, the folate has a targeting function, and the polylactic acid long chain has hydrophobicity. The raltitrexed drug is embedded in the micelle core of the copolymer, so that the encapsulation rate is greatly improved. The raltitrexed molecule contains O, N, S and other elements, can easily form a hydrogen bond with the amphiphilic copolymer, the hydrophobic end polylactic acid side chain can prolong the drug release time, achieve the purpose of slow release, reduce the drug toxicity and adverse reactions, the prepared composition is relatively stable in release, and the slow release effect is relatively ideal.

This invention provides an siRNA for inhibiting MSTN gene expression, its conjugates, and their applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises nucleotide sequence I, and the antisense strand comprises nucleotide sequence II; each nucleotide in nucleotide sequence I and nucleotide sequence II is a modified or unmodified nucleotide. The siRNA, its conjugates, and the pharmaceutical composition provided by this invention exhibit strong inhibitory activity against the MSTN gene, significantly reducing the expression level of MSTN mRNA, and have low drug toxicity.

The application discloses an IL12 mutant fusion protein and application thereof. Specifically disclosed are a fusion protein comprising an antibody binding to human PD1 and an IL12 mutant protein and a preparation method and therapeutic use thereof, wherein the IL12 mutant protein is obtained by mutation and modification of a wild-type P40 subunit. The fusion protein of the application has reduced binding capacity to an IL12 receptor, reduced drug toxicity of IL12, and obviously improved drugability of a cytokine. Meanwhile, through the specificity of the antibody, the fusion protein effectively enhances the targeting of the cytokine, weakens the potential toxicity of the cytokine, can exert the dual functions of the PD1 antibody and the IL12 cytokine, and thus has better anti-tumor potential. The fusion protein of the application can obviously inhibit tumor growth, has high anti-tumor effect, can prolong the half-life, reduce the administration frequency, has high safety, and has good clinical transformation value and broad application prospect.

The present application relates to the technical field of medicine, in particular to a kind of composition for treating IDH1 mutation and mutant drug resistance and application thereof, the composition is composed of AG120 and phosphatidyl ethanolamine (PE).The present application finds that the composition containing AG120 and PE can synergistically reduce the expression of IDH1 mutant carcinogenic metabolite 2-HG and inhibit tumor growth;And improve the therapeutic effect after IDH1 mutant solid tumor is resistant to AG120, can reduce the expression of IDH1 mutant drug-resistant tumor cell carcinogenic metabolite 2-HG and inhibit its tumor growth;The effect of combination group is obviously superior to the group of AG120 used alone.At the same time, the pharmaceutical composition is not found in the process of application treatment that mouse weight reduces and obvious drug toxicity.

This invention provides a modular precision intervention step-color bioactive system based on traditional constitution theory, relating to the field of biomedical technology. It comprises the following modules: a step-color module providing basic visual interaction, consisting of a physically separated first and second component; a multi-source precision intervention module including at least five independently pre-packaged bioactive functional units, each with a preset weight corresponding to one of the five constitution types in traditional constitution theory; and a stabilization module including buffer water composed of sodium bicarbonate, potassium chloride, and magnesium sulfate to provide a daily support dose for the corresponding constitution. All functional ingredients in the formulations of this invention are derived from the list of substances with medicinal and edible homology or common food ingredients, ensuring their legality and safety for consumption. The dosage design strictly adheres to safety guidelines, avoiding the risk of drug toxicity and side effects.

The application discloses a resiquimod polymer nanodrug and a preparation method and application thereof, and belongs to the technical field of medicines. The resiquimod polymer nanodrug has a structure shown in formula 1, and as ROS response resiquimod prodrug nanodrug (R848NPs), realizes selective activation of the drug at a tumor site, effectively reduces drug toxicity, and has good antitumor effect. The R848NPs effectively reduce drug toxicity by closing the pharmacophore amino group of the small molecule drug resiquimod, avoid the occurrence of immune-related adverse reactions after systemic administration, and introduce a ROS response bond, so that the small molecule original drug R848 is released through the action of an endogenous stimulator ROS in a high ROS environment at the tumor site, and good efficacy is achieved. In addition, when the ROS response resiquimod prodrug nanodrug is combined with ultrasound and alphaPDL1, the tumor inhibition rate can reach 99.0%.

This invention discloses the application of necrotizing 1 (Necrostatin-1) in the preparation of drugs for the prevention and / or treatment of dry eye, relating to the field of biomedical technology. The application of necrotizing 1 in the preparation of drugs for the prevention and / or treatment of dry eye is described. This invention is the first to discover the application of the programmed necrosis inhibitor Necrostatin-1 in the treatment of dry eye. Nec-1, by inhibiting programmed necrosis, can effectively protect corneal epithelial cells and reduce ocular surface inflammation and damage. In a scopolamine-induced dry eye model, subconjunctival injection of 0.3 μM Nec-1 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, without significant drug toxicity. Nec-1 provides a new targeting strategy for dry eye treatment and may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention discloses a near-infrared photoactivated nitrogen mustard drug compound, its preparation method, and its applications. The general structural formula of the near-infrared photoactivated nitrogen mustard drug compound is shown below: where R1 and R2 are both optionally selected from methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl. This compound reduces the toxic side effects of nitrogen mustard through a prodrug strategy. This compound utilizes the synergistic effect of nitrogen mustard chemotherapy and photodynamic therapy with a photosensitizer to effectively inhibit tumor growth. Simultaneously, the introduction of the photosensitizer imparts fluorescence changes before and after nitrogen mustard drug release, enabling visualization of drug release. This compound has broad application prospects in reducing drug toxicity and anti-tumor activity. The near-infrared photoactivated nitrogen mustard prodrug / drug preparation method provided by this invention is simple, uses inexpensive and readily available raw materials, has a simple synthesis process, and is easy to separate and purify, making it suitable for large-scale production and widespread application.